An evaluation of screening tests for defects in the protein C pathway: Commercial kits lack sensitivity and specificity

Blood Coagulation and Fibrinolysis

Volumn 13, Issue 2, 2002, Pages 155-163

  Gardiner, C ^a   Cooper, P C ^a   Makris, M ^a   Mackie, I J ^a   Malia, R G ^a   Machin, S J ^a  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Factor V Leiden; Protein C pathway; Sensitivity; Specificity

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; LUPUS ANTICOAGULANT; PROTEIN C; PROTEIN S;

ARTICLE; BIOASSAY; BLOOD CLOTTING; BLOOD LEVEL; CONTROLLED STUDY; EVALUATION; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; SAMPLING; SCREENING TEST; THROMBOPHILIA; ANALYTICAL EQUIPMENT; BLOOD CLOTTING TEST; COMPARATIVE STUDY; MASS SCREENING; METABOLISM; METHODOLOGY; REFERENCE VALUE; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STANDARD;

BLOOD COAGULATION TESTS; FEMALE; HUMANS; MALE; MASS SCREENING; PROTEIN C; REAGENT KITS, DIAGNOSTIC; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; THROMBOPHILIA;

EID: 0036489809     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200203000-00011     Document Type: Article

References (30)

1. British Committee for Standards in Haematology Guidelines on the investigation and management of heritable thrombophilia
2. Blood coagulation. The thrombin paradox
3. Factor V Leiden and other coagulation factor mutations affecting thrombotic risk
4. The endothelial cell protein C receptor
5. Risk factors for venous thrombosis: Prevalence, risk, and interaction
6. Proc Global: The first functional screening assay for the complete protein C pathway
7. A more discriminating test for APC resistance and a possible screening test to include protein C and protein S
8. Use of a generally applicable tissue factor-dependent factor V assay to detect activated protein C-resistant factor Va in patients receiving warfarin and in patients with a lupus anticoagulant
9. Medical Devices Agency evaluation of kits for the assessment of the protein C pathway
10. Guidelines on the investigation and management of the antiphospholipid syndrome
11. The simultaneous measurement of total and free protein S by ELISA
12. Simultaneous assay of free and total protein S by ELISA using monoclonal and polyclonal antibodies
13. The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants
14. Mutation in blood coagulation factor V associated with resistance to activated protein C
15. The impact of oral anticoagulation therapy, factor VIII level and the quality of factor V deficient plasma on three commercial methods for activated protein C resistance
16. Oral contraceptives venous thrombosis: Different sensitivities to activated protein C in women using second- and third- generation oral contraceptives
17. Screening for identified and unidentified protein C pathway defects by the Agkistrodon contortrix venom test in consecutive patients
18. ProC Global screening test and the risk of thrombosis
19. Screening for abnormalities of the protein C anticoagulant pathway using the ProC Global assay. Results of a European multicenter evaluation
20. Evaluation of a new screening assay ProC Global for identification of defects in the protein C/protein S anticoagulant pathway
21. Laboratory screening of thrombophilia. Evaluation of the diagnostic efficacy of a global test to detect congenital deficiencies of the protein C anticoagulant pathway
22. A protein C pathway (PCP) screening test for the detection of APC resistance and protein C or S deficiencies
23. Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies
24. Impaired catalytic function of activated protein C: A new in vitro manifestation of lupus anticoagulant
25. A new variant of interaction between phospholipid antibodies and the protein C system
26. Characterization of beta2-glycoprotein I binding to phospholipid membranes
27. Activated protein C resistance: Effect of platelet activation, platelet-derived microparticles, atherogenic lipoproteins
28. Cold promoted activation and factor XII, prekallikrein and C1-inhibitor
29. Cold-induced contact surface activation of the prothrombin time in whole blood
30. Stability of coagulation proteins in frozen plasma